Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Urinary Bladder Neoplasms | 81 | 2024 | 2195 | 10.900 |
Why?
|
Cystectomy | 47 | 2024 | 603 | 8.220 |
Why?
|
Prostatic Neoplasms | 122 | 2024 | 11101 | 6.590 |
Why?
|
Carcinoma, Transitional Cell | 15 | 2023 | 794 | 3.200 |
Why?
|
Androgen Antagonists | 31 | 2024 | 1412 | 3.170 |
Why?
|
Radiation Oncology | 15 | 2022 | 572 | 2.850 |
Why?
|
Neoplasm Invasiveness | 41 | 2024 | 3620 | 2.060 |
Why?
|
Urinary Bladder | 24 | 2024 | 1157 | 2.050 |
Why?
|
Radiotherapy, Intensity-Modulated | 16 | 2021 | 798 | 2.010 |
Why?
|
Prostatectomy | 23 | 2024 | 1786 | 1.890 |
Why?
|
Seminoma | 6 | 2023 | 136 | 1.660 |
Why?
|
Prostate-Specific Antigen | 30 | 2024 | 2463 | 1.610 |
Why?
|
Antineoplastic Agents, Hormonal | 10 | 2020 | 1536 | 1.550 |
Why?
|
Salvage Therapy | 15 | 2024 | 1273 | 1.520 |
Why?
|
Watchful Waiting | 6 | 2023 | 492 | 1.510 |
Why?
|
Photons | 4 | 2021 | 594 | 1.500 |
Why?
|
Radiotherapy, Adjuvant | 15 | 2018 | 1791 | 1.420 |
Why?
|
Radiotherapy | 17 | 2022 | 1502 | 1.360 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 17 | 2023 | 1679 | 1.360 |
Why?
|
Combined Modality Therapy | 32 | 2024 | 8542 | 1.340 |
Why?
|
Urethral Neoplasms | 4 | 2017 | 37 | 1.340 |
Why?
|
Neoplasm Recurrence, Local | 25 | 2024 | 9419 | 1.310 |
Why?
|
Testicular Neoplasms | 7 | 2023 | 806 | 1.300 |
Why?
|
Goserelin | 4 | 2015 | 126 | 1.090 |
Why?
|
Chemotherapy, Adjuvant | 14 | 2021 | 3556 | 1.070 |
Why?
|
Radiotherapy Dosage | 27 | 2023 | 2916 | 1.050 |
Why?
|
Muscles | 11 | 2023 | 1582 | 0.990 |
Why?
|
Male | 185 | 2024 | 364719 | 0.900 |
Why?
|
Neoplasm Staging | 33 | 2024 | 11244 | 0.890 |
Why?
|
Brachytherapy | 11 | 2020 | 1220 | 0.870 |
Why?
|
Humans | 261 | 2024 | 768166 | 0.810 |
Why?
|
Muscle Neoplasms | 3 | 2018 | 130 | 0.810 |
Why?
|
Adenocarcinoma | 11 | 2023 | 6395 | 0.810 |
Why?
|
Medical Oncology | 6 | 2020 | 2346 | 0.790 |
Why?
|
Hospitals, General | 3 | 2017 | 809 | 0.790 |
Why?
|
Flutamide | 2 | 2015 | 95 | 0.780 |
Why?
|
Radiotherapy, Conformal | 9 | 2018 | 549 | 0.760 |
Why?
|
Organs at Risk | 7 | 2021 | 367 | 0.740 |
Why?
|
Disease-Free Survival | 20 | 2024 | 6847 | 0.720 |
Why?
|
Carcinoma | 6 | 2017 | 2332 | 0.720 |
Why?
|
BCG Vaccine | 5 | 2024 | 381 | 0.710 |
Why?
|
Kaplan-Meier Estimate | 14 | 2020 | 6526 | 0.670 |
Why?
|
Lymph Nodes | 6 | 2023 | 3474 | 0.670 |
Why?
|
Treatment Outcome | 58 | 2023 | 65371 | 0.660 |
Why?
|
Aged | 85 | 2024 | 171504 | 0.650 |
Why?
|
Urologic Surgical Procedures | 3 | 2018 | 281 | 0.630 |
Why?
|
Neoadjuvant Therapy | 11 | 2023 | 2907 | 0.620 |
Why?
|
Rectum | 11 | 2021 | 900 | 0.610 |
Why?
|
Cisplatin | 10 | 2024 | 1660 | 0.600 |
Why?
|
Orchiectomy | 3 | 2023 | 466 | 0.600 |
Why?
|
Insurance Coverage | 4 | 2022 | 1946 | 0.590 |
Why?
|
Paclitaxel | 2 | 2023 | 1733 | 0.580 |
Why?
|
Quality of Life | 20 | 2024 | 13490 | 0.580 |
Why?
|
Proportional Hazards Models | 18 | 2024 | 12543 | 0.570 |
Why?
|
Urothelium | 2 | 2016 | 275 | 0.560 |
Why?
|
Neoplasms | 16 | 2022 | 22371 | 0.550 |
Why?
|
X-Ray Therapy | 1 | 2016 | 8 | 0.550 |
Why?
|
Protons | 6 | 2021 | 1113 | 0.540 |
Why?
|
Leuprolide | 2 | 2015 | 313 | 0.530 |
Why?
|
Personal Autonomy | 1 | 2018 | 315 | 0.520 |
Why?
|
Carcinoma, Squamous Cell | 6 | 2017 | 4058 | 0.510 |
Why?
|
Developing Countries | 4 | 2015 | 2910 | 0.500 |
Why?
|
Botswana | 12 | 2024 | 1058 | 0.500 |
Why?
|
Healthcare Disparities | 6 | 2022 | 3415 | 0.490 |
Why?
|
Middle Aged | 79 | 2024 | 223492 | 0.490 |
Why?
|
Paintings | 1 | 2016 | 102 | 0.480 |
Why?
|
Prostate | 10 | 2024 | 1765 | 0.480 |
Why?
|
Cancer Care Facilities | 3 | 2015 | 427 | 0.480 |
Why?
|
Urethra | 3 | 2018 | 406 | 0.480 |
Why?
|
Multivariate Analysis | 14 | 2018 | 12077 | 0.470 |
Why?
|
Radiation Injuries | 6 | 2017 | 1198 | 0.450 |
Why?
|
Propensity Score | 5 | 2023 | 1969 | 0.450 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2018 | 620 | 0.440 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 11 | 2024 | 11878 | 0.440 |
Why?
|
Radiation-Sensitizing Agents | 3 | 2024 | 348 | 0.440 |
Why?
|
Stromal Cells | 1 | 2019 | 1336 | 0.430 |
Why?
|
Postoperative Care | 3 | 2018 | 1480 | 0.420 |
Why?
|
Lymphatic Metastasis | 7 | 2018 | 2914 | 0.410 |
Why?
|
Evidence-Based Medicine | 9 | 2024 | 3706 | 0.400 |
Why?
|
Survival Rate | 11 | 2019 | 12840 | 0.390 |
Why?
|
Cadherins | 5 | 2001 | 905 | 0.390 |
Why?
|
Program Evaluation | 3 | 2022 | 2507 | 0.390 |
Why?
|
Time Factors | 25 | 2024 | 40218 | 0.380 |
Why?
|
Neoplasms, Hormone-Dependent | 2 | 2014 | 410 | 0.380 |
Why?
|
Faculty, Medical | 2 | 2022 | 1226 | 0.370 |
Why?
|
Deoxycytidine | 3 | 2024 | 887 | 0.370 |
Why?
|
Retrospective Studies | 38 | 2024 | 81762 | 0.370 |
Why?
|
Radiation Tolerance | 5 | 2016 | 476 | 0.360 |
Why?
|
Aged, 80 and over | 31 | 2024 | 59629 | 0.350 |
Why?
|
Patient Care Management | 1 | 2013 | 303 | 0.340 |
Why?
|
Cardiovascular Diseases | 4 | 2024 | 15662 | 0.330 |
Why?
|
Male Urogenital Diseases | 1 | 2009 | 48 | 0.330 |
Why?
|
Survivors | 2 | 2017 | 2381 | 0.320 |
Why?
|
Relative Biological Effectiveness | 5 | 2017 | 313 | 0.320 |
Why?
|
Urology | 3 | 2023 | 384 | 0.320 |
Why?
|
Immunotherapy | 5 | 2023 | 4755 | 0.310 |
Why?
|
Evidence-Based Practice | 1 | 2013 | 500 | 0.310 |
Why?
|
Referral and Consultation | 4 | 2014 | 3620 | 0.310 |
Why?
|
Epidemics | 1 | 2014 | 517 | 0.300 |
Why?
|
Follow-Up Studies | 18 | 2024 | 39348 | 0.300 |
Why?
|
Patient Care Team | 3 | 2018 | 2523 | 0.300 |
Why?
|
Cost-Benefit Analysis | 2 | 2019 | 5536 | 0.300 |
Why?
|
Growth Substances | 3 | 1999 | 759 | 0.300 |
Why?
|
Treatment Failure | 6 | 2024 | 2661 | 0.290 |
Why?
|
Hydrogels | 3 | 2023 | 744 | 0.290 |
Why?
|
Social Class | 1 | 2016 | 2008 | 0.280 |
Why?
|
Female | 57 | 2024 | 397192 | 0.280 |
Why?
|
Insurance, Health | 2 | 2016 | 2517 | 0.280 |
Why?
|
Fluorouracil | 3 | 2024 | 1652 | 0.270 |
Why?
|
Delivery of Health Care | 2 | 2015 | 5367 | 0.270 |
Why?
|
Odds Ratio | 8 | 2016 | 9669 | 0.270 |
Why?
|
Interdisciplinary Communication | 1 | 2012 | 937 | 0.270 |
Why?
|
Pelvis | 3 | 2020 | 736 | 0.260 |
Why?
|
Capacity Building | 3 | 2019 | 265 | 0.260 |
Why?
|
Prognosis | 13 | 2024 | 30010 | 0.260 |
Why?
|
Consensus | 8 | 2024 | 3212 | 0.260 |
Why?
|
Neoplasms, Second Primary | 2 | 2023 | 1061 | 0.250 |
Why?
|
Mucins | 2 | 1999 | 570 | 0.240 |
Why?
|
Hormones | 3 | 2023 | 866 | 0.240 |
Why?
|
Mentors | 2 | 2022 | 671 | 0.240 |
Why?
|
Boston | 5 | 2017 | 9374 | 0.240 |
Why?
|
Body Mass Index | 6 | 2014 | 13053 | 0.230 |
Why?
|
United States | 25 | 2024 | 73039 | 0.230 |
Why?
|
Guideline Adherence | 2 | 2013 | 2235 | 0.230 |
Why?
|
Risk Factors | 20 | 2023 | 74944 | 0.220 |
Why?
|
Hodgkin Disease | 2 | 2022 | 1384 | 0.220 |
Why?
|
Randomized Controlled Trials as Topic | 12 | 2022 | 10399 | 0.220 |
Why?
|
Health Services Accessibility | 3 | 2016 | 5520 | 0.220 |
Why?
|
Muscle Proteins | 2 | 1999 | 1165 | 0.210 |
Why?
|
Health Care Costs | 2 | 2013 | 3239 | 0.210 |
Why?
|
Cyclooxygenase Inhibitors | 1 | 2005 | 361 | 0.210 |
Why?
|
Ataxia Telangiectasia | 1 | 2023 | 107 | 0.210 |
Why?
|
Prospective Studies | 17 | 2023 | 54926 | 0.210 |
Why?
|
Neuropeptides | 2 | 1999 | 951 | 0.210 |
Why?
|
Fiducial Markers | 2 | 2021 | 134 | 0.200 |
Why?
|
Adult | 30 | 2024 | 223646 | 0.200 |
Why?
|
HIV Infections | 7 | 2024 | 17569 | 0.200 |
Why?
|
Databases, Factual | 9 | 2019 | 8080 | 0.200 |
Why?
|
Neoplasm Metastasis | 6 | 2021 | 4912 | 0.200 |
Why?
|
Dose-Response Relationship, Radiation | 3 | 2016 | 876 | 0.190 |
Why?
|
Kidney Neoplasms | 2 | 2020 | 4282 | 0.190 |
Why?
|
Logistic Models | 7 | 2016 | 13290 | 0.190 |
Why?
|
Radiosurgery | 2 | 2024 | 1330 | 0.190 |
Why?
|
Cyclobutanes | 1 | 2021 | 57 | 0.180 |
Why?
|
Carboxylic Acids | 1 | 2021 | 91 | 0.180 |
Why?
|
Data Mining | 2 | 2016 | 563 | 0.180 |
Why?
|
Gastrointestinal Diseases | 1 | 2009 | 1206 | 0.180 |
Why?
|
Disease Management | 5 | 2019 | 2536 | 0.170 |
Why?
|
Muscle, Smooth | 2 | 2014 | 931 | 0.170 |
Why?
|
Registries | 4 | 2021 | 8375 | 0.170 |
Why?
|
Radiology Information Systems | 1 | 2024 | 533 | 0.170 |
Why?
|
Polymorphism, Single-Stranded Conformational | 2 | 2001 | 325 | 0.170 |
Why?
|
Endometriosis | 2 | 2005 | 873 | 0.170 |
Why?
|
Uterine Cervical Neoplasms | 4 | 2016 | 2043 | 0.170 |
Why?
|
Radiation Dosage | 4 | 2020 | 1967 | 0.170 |
Why?
|
Incidence | 8 | 2023 | 21538 | 0.160 |
Why?
|
Patient Selection | 6 | 2018 | 4260 | 0.160 |
Why?
|
DNA Repair | 3 | 2023 | 2050 | 0.160 |
Why?
|
Rectal Diseases | 1 | 2020 | 142 | 0.160 |
Why?
|
Digestive System Physiological Phenomena | 1 | 1998 | 15 | 0.160 |
Why?
|
Seminal Vesicles | 5 | 2021 | 101 | 0.160 |
Why?
|
Cohort Studies | 14 | 2023 | 41754 | 0.160 |
Why?
|
Carcinoma, Renal Cell | 1 | 2014 | 3187 | 0.150 |
Why?
|
Tyrphostins | 1 | 1998 | 63 | 0.150 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2023 | 498 | 0.150 |
Why?
|
Nomograms | 3 | 2021 | 236 | 0.150 |
Why?
|
Cell Adhesion | 4 | 1999 | 3096 | 0.150 |
Why?
|
Phthalazines | 2 | 2018 | 397 | 0.150 |
Why?
|
Antibodies, Monoclonal | 1 | 2015 | 9263 | 0.150 |
Why?
|
Quality of Health Care | 1 | 2013 | 4310 | 0.150 |
Why?
|
Antineoplastic Agents | 10 | 2023 | 13676 | 0.150 |
Why?
|
Disease Progression | 6 | 2023 | 13671 | 0.150 |
Why?
|
Delivery of Health Care, Integrated | 2 | 2017 | 951 | 0.150 |
Why?
|
Cyclonic Storms | 1 | 2019 | 121 | 0.140 |
Why?
|
Urination Disorders | 2 | 2016 | 236 | 0.140 |
Why?
|
Urogenital Neoplasms | 1 | 2018 | 130 | 0.140 |
Why?
|
Africa South of the Sahara | 2 | 2021 | 752 | 0.140 |
Why?
|
Kallikreins | 2 | 2015 | 219 | 0.140 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 2 | 2024 | 1105 | 0.140 |
Why?
|
Internationality | 2 | 2020 | 1008 | 0.140 |
Why?
|
DNA Breaks, Double-Stranded | 3 | 2018 | 606 | 0.140 |
Why?
|
Posters as Topic | 1 | 2016 | 6 | 0.140 |
Why?
|
Folklore | 1 | 2016 | 7 | 0.140 |
Why?
|
Consensus Development Conferences, NIH as Topic | 1 | 2016 | 29 | 0.140 |
Why?
|
Hospitals, Community | 2 | 2016 | 365 | 0.130 |
Why?
|
Survival Analysis | 6 | 2019 | 10101 | 0.130 |
Why?
|
Colonic Neoplasms | 2 | 1999 | 2541 | 0.130 |
Why?
|
Medicine in Literature | 1 | 2016 | 32 | 0.130 |
Why?
|
Androstenes | 1 | 2018 | 177 | 0.130 |
Why?
|
Peptides | 2 | 1999 | 4354 | 0.130 |
Why?
|
Career Mobility | 1 | 2018 | 262 | 0.130 |
Why?
|
Practice Guidelines as Topic | 6 | 2024 | 7454 | 0.130 |
Why?
|
Radium | 1 | 2016 | 70 | 0.130 |
Why?
|
Regression Analysis | 5 | 2018 | 6340 | 0.130 |
Why?
|
Recombinases | 1 | 2016 | 70 | 0.130 |
Why?
|
Biopsy | 5 | 2024 | 6793 | 0.130 |
Why?
|
Cytoskeletal Proteins | 2 | 1998 | 1327 | 0.130 |
Why?
|
Neoplastic Cells, Circulating | 2 | 2023 | 952 | 0.120 |
Why?
|
Information Management | 1 | 2015 | 100 | 0.120 |
Why?
|
SEER Program | 6 | 2016 | 1444 | 0.120 |
Why?
|
Risk Assessment | 6 | 2016 | 24315 | 0.120 |
Why?
|
Administration, Intravesical | 3 | 2023 | 88 | 0.120 |
Why?
|
RNA, Neoplasm | 1 | 2018 | 749 | 0.120 |
Why?
|
Clinical Trials as Topic | 4 | 2023 | 8054 | 0.120 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2019 | 343 | 0.120 |
Why?
|
Hematuria | 1 | 2016 | 232 | 0.120 |
Why?
|
Sulfonamides | 1 | 2005 | 1982 | 0.120 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2005 | 2271 | 0.120 |
Why?
|
Acquired Immunodeficiency Syndrome | 2 | 2014 | 2204 | 0.120 |
Why?
|
Statistics, Nonparametric | 3 | 2016 | 2862 | 0.120 |
Why?
|
Ifosfamide | 1 | 2015 | 233 | 0.120 |
Why?
|
Urinary Diversion | 1 | 2015 | 134 | 0.120 |
Why?
|
Forefoot, Human | 1 | 2014 | 31 | 0.120 |
Why?
|
Carboplatin | 2 | 2015 | 797 | 0.120 |
Why?
|
Mitomycin | 1 | 2015 | 261 | 0.120 |
Why?
|
Fanconi Anemia Complementation Group D2 Protein | 1 | 2015 | 148 | 0.120 |
Why?
|
Hospitals, Teaching | 2 | 2016 | 1157 | 0.110 |
Why?
|
Pyrazoles | 1 | 2005 | 2028 | 0.110 |
Why?
|
Condylomata Acuminata | 1 | 2014 | 79 | 0.110 |
Why?
|
Medicaid | 3 | 2016 | 2840 | 0.110 |
Why?
|
Penis | 4 | 2018 | 209 | 0.110 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2021 | 1375 | 0.110 |
Why?
|
Uterine Cervical Diseases | 1 | 2014 | 75 | 0.110 |
Why?
|
Community Health Centers | 1 | 2017 | 469 | 0.110 |
Why?
|
Cost Savings | 1 | 2019 | 904 | 0.110 |
Why?
|
Vascular Endothelial Growth Factor B | 1 | 2013 | 25 | 0.110 |
Why?
|
DNA Methylation | 3 | 2023 | 4428 | 0.110 |
Why?
|
Urologic Diseases | 1 | 2016 | 246 | 0.110 |
Why?
|
Predictive Value of Tests | 5 | 2018 | 15454 | 0.110 |
Why?
|
Vaginal Neoplasms | 1 | 2014 | 105 | 0.110 |
Why?
|
Medically Uninsured | 2 | 2016 | 840 | 0.110 |
Why?
|
Age Factors | 9 | 2022 | 18412 | 0.110 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 3 | 2019 | 5432 | 0.110 |
Why?
|
Universities | 1 | 2018 | 1005 | 0.110 |
Why?
|
Disasters | 1 | 2019 | 521 | 0.110 |
Why?
|
Comparative Effectiveness Research | 1 | 2018 | 714 | 0.110 |
Why?
|
Interinstitutional Relations | 1 | 2014 | 235 | 0.110 |
Why?
|
Endonucleases | 1 | 2016 | 371 | 0.110 |
Why?
|
Equipment and Supplies | 1 | 2015 | 274 | 0.110 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2016 | 364 | 0.100 |
Why?
|
Uterine Hemorrhage | 1 | 2014 | 236 | 0.100 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2015 | 719 | 0.100 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2016 | 594 | 0.100 |
Why?
|
Penile Neoplasms | 1 | 2014 | 158 | 0.100 |
Why?
|
Quality Assurance, Health Care | 2 | 2013 | 2176 | 0.100 |
Why?
|
Medicare | 3 | 2022 | 6809 | 0.100 |
Why?
|
Movement | 3 | 2015 | 1490 | 0.100 |
Why?
|
Personnel Staffing and Scheduling | 1 | 2015 | 497 | 0.100 |
Why?
|
Intestinal Diseases | 1 | 2016 | 505 | 0.100 |
Why?
|
Database Management Systems | 1 | 2013 | 263 | 0.100 |
Why?
|
Molecular Imaging | 1 | 2018 | 826 | 0.100 |
Why?
|
Radiometry | 2 | 2017 | 818 | 0.100 |
Why?
|
Trans-Activators | 2 | 1998 | 2857 | 0.100 |
Why?
|
Minority Groups | 2 | 2016 | 1216 | 0.100 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2021 | 1437 | 0.090 |
Why?
|
Costs and Cost Analysis | 2 | 2016 | 1667 | 0.090 |
Why?
|
Research Design | 3 | 2023 | 6211 | 0.090 |
Why?
|
Marital Status | 1 | 2012 | 426 | 0.090 |
Why?
|
Androgens | 3 | 2023 | 1281 | 0.090 |
Why?
|
Cone-Beam Computed Tomography | 1 | 2015 | 459 | 0.090 |
Why?
|
DNA Damage | 2 | 2023 | 2469 | 0.090 |
Why?
|
Interferon-gamma | 1 | 2019 | 3160 | 0.090 |
Why?
|
Consumer Health Information | 1 | 2012 | 215 | 0.090 |
Why?
|
Piperazines | 2 | 2018 | 2554 | 0.090 |
Why?
|
Advisory Committees | 1 | 2014 | 797 | 0.080 |
Why?
|
Reactive Oxygen Species | 1 | 2018 | 2149 | 0.080 |
Why?
|
Mammography | 1 | 2021 | 2433 | 0.080 |
Why?
|
Carcinoma, Ductal | 1 | 2010 | 97 | 0.080 |
Why?
|
Quality Indicators, Health Care | 1 | 2019 | 1805 | 0.080 |
Why?
|
Patient-Centered Care | 1 | 2019 | 1444 | 0.080 |
Why?
|
Genomics | 5 | 2023 | 5926 | 0.080 |
Why?
|
ras Proteins | 1 | 2014 | 1058 | 0.080 |
Why?
|
Nephrectomy | 1 | 2014 | 930 | 0.080 |
Why?
|
Intestines | 2 | 2022 | 1909 | 0.080 |
Why?
|
BRCA1 Protein | 1 | 2015 | 1155 | 0.080 |
Why?
|
History, 20th Century | 1 | 2016 | 2766 | 0.080 |
Why?
|
Terminology as Topic | 1 | 2015 | 1542 | 0.080 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2018 | 2954 | 0.080 |
Why?
|
Uncertainty | 1 | 2013 | 769 | 0.080 |
Why?
|
Diphosphonates | 1 | 2013 | 634 | 0.070 |
Why?
|
Gastrins | 2 | 1998 | 75 | 0.070 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2012 | 542 | 0.070 |
Why?
|
Lymphocyte Activation | 1 | 2019 | 5505 | 0.070 |
Why?
|
Adjuvants, Immunologic | 2 | 2023 | 998 | 0.070 |
Why?
|
Physicians | 2 | 2017 | 4598 | 0.070 |
Why?
|
Societies, Medical | 4 | 2024 | 3968 | 0.070 |
Why?
|
Multicenter Studies as Topic | 3 | 2022 | 1737 | 0.070 |
Why?
|
Lung Neoplasms | 3 | 2019 | 13586 | 0.070 |
Why?
|
Perioperative Care | 1 | 2015 | 1043 | 0.070 |
Why?
|
Quality Improvement | 2 | 2013 | 3857 | 0.070 |
Why?
|
Risk | 2 | 2019 | 9613 | 0.070 |
Why?
|
Homeostasis | 1 | 1998 | 3348 | 0.070 |
Why?
|
Gene Expression Profiling | 2 | 2020 | 9538 | 0.070 |
Why?
|
Imidazoles | 1 | 2013 | 1169 | 0.070 |
Why?
|
Organ Size | 3 | 2020 | 2267 | 0.070 |
Why?
|
Massachusetts | 2 | 2017 | 8890 | 0.070 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2018 | 2815 | 0.070 |
Why?
|
Epithelial Cells | 1 | 1998 | 3703 | 0.070 |
Why?
|
Cross-Sectional Studies | 4 | 2023 | 26379 | 0.060 |
Why?
|
Population Surveillance | 1 | 2016 | 2596 | 0.060 |
Why?
|
Medical Informatics | 1 | 2013 | 743 | 0.060 |
Why?
|
Cobalt Radioisotopes | 2 | 2016 | 75 | 0.060 |
Why?
|
Neoplasm Proteins | 1 | 1998 | 3603 | 0.060 |
Why?
|
Mutation | 8 | 2024 | 30238 | 0.060 |
Why?
|
Patient Education as Topic | 2 | 2012 | 2337 | 0.060 |
Why?
|
Bone Density Conservation Agents | 1 | 2013 | 797 | 0.060 |
Why?
|
Obesity | 1 | 2007 | 13090 | 0.060 |
Why?
|
Africa | 2 | 2019 | 725 | 0.060 |
Why?
|
Endostatins | 1 | 2005 | 167 | 0.060 |
Why?
|
Breast Neoplasms | 2 | 2024 | 21206 | 0.060 |
Why?
|
Gene Expression Regulation, Neoplastic | 6 | 2018 | 8647 | 0.060 |
Why?
|
Particle Size | 1 | 2009 | 1649 | 0.060 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2010 | 709 | 0.060 |
Why?
|
Cost of Illness | 1 | 2015 | 1951 | 0.060 |
Why?
|
Rad51 Recombinase | 2 | 2016 | 191 | 0.060 |
Why?
|
Neovascularization, Physiologic | 1 | 2012 | 1369 | 0.060 |
Why?
|
Linear Energy Transfer | 2 | 2016 | 154 | 0.060 |
Why?
|
Nitriles | 2 | 2021 | 980 | 0.060 |
Why?
|
Technology, Radiologic | 2 | 2016 | 160 | 0.060 |
Why?
|
Comorbidity | 3 | 2016 | 10590 | 0.060 |
Why?
|
Pilot Projects | 2 | 2017 | 8741 | 0.060 |
Why?
|
Weight Gain | 1 | 2014 | 2359 | 0.060 |
Why?
|
Xeroderma Pigmentosum Group D Protein | 1 | 2023 | 105 | 0.050 |
Why?
|
Femur Head | 2 | 2018 | 297 | 0.050 |
Why?
|
Biomedical Research | 2 | 2015 | 3463 | 0.050 |
Why?
|
Young Adult | 5 | 2020 | 60066 | 0.050 |
Why?
|
Testosterone | 1 | 2014 | 2491 | 0.050 |
Why?
|
Fanconi Anemia | 2 | 2016 | 327 | 0.050 |
Why?
|
Animals | 12 | 2023 | 169246 | 0.050 |
Why?
|
Patient Participation | 1 | 2012 | 1447 | 0.050 |
Why?
|
Overweight | 1 | 2014 | 2448 | 0.050 |
Why?
|
MicroRNAs | 1 | 2018 | 3803 | 0.050 |
Why?
|
Tumor Cells, Cultured | 3 | 1999 | 6124 | 0.050 |
Why?
|
Longitudinal Studies | 1 | 2018 | 14783 | 0.050 |
Why?
|
Papillomavirus Infections | 1 | 2014 | 1640 | 0.050 |
Why?
|
Chromatin | 1 | 2014 | 2981 | 0.050 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2023 | 428 | 0.050 |
Why?
|
Proto-Oncogene Proteins | 1 | 2014 | 4528 | 0.050 |
Why?
|
alpha Catenin | 2 | 1998 | 37 | 0.050 |
Why?
|
Patient Compliance | 1 | 2012 | 2697 | 0.050 |
Why?
|
Radiography | 4 | 2015 | 6983 | 0.050 |
Why?
|
Liver Regeneration | 1 | 2003 | 214 | 0.050 |
Why?
|
Desmoplakins | 2 | 1998 | 63 | 0.050 |
Why?
|
T-Lymphocytes | 1 | 2019 | 10266 | 0.050 |
Why?
|
Tosyl Compounds | 1 | 2021 | 115 | 0.050 |
Why?
|
Fertility | 1 | 2005 | 771 | 0.040 |
Why?
|
Patient Satisfaction | 1 | 2013 | 3488 | 0.040 |
Why?
|
Cell Line, Tumor | 5 | 2018 | 17140 | 0.040 |
Why?
|
Internet | 1 | 2012 | 3110 | 0.040 |
Why?
|
Delphi Technique | 1 | 2024 | 891 | 0.040 |
Why?
|
Frameshift Mutation | 2 | 1999 | 392 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 3 | 2023 | 36743 | 0.040 |
Why?
|
Decision Support Techniques | 1 | 2010 | 2008 | 0.040 |
Why?
|
Colorectal Neoplasms | 4 | 2001 | 6974 | 0.040 |
Why?
|
BK Virus | 1 | 2020 | 120 | 0.040 |
Why?
|
Data Collection | 2 | 2021 | 3327 | 0.040 |
Why?
|
Hepatectomy | 1 | 2003 | 588 | 0.040 |
Why?
|
Analysis of Variance | 1 | 2008 | 6229 | 0.040 |
Why?
|
Lymph Node Excision | 2 | 2017 | 1271 | 0.040 |
Why?
|
Genes, APC | 1 | 1999 | 145 | 0.040 |
Why?
|
Software | 1 | 2013 | 4478 | 0.040 |
Why?
|
Base Pairing | 1 | 1999 | 139 | 0.040 |
Why?
|
Recombinant Proteins | 2 | 1999 | 6514 | 0.040 |
Why?
|
DNA-Binding Proteins | 1 | 2016 | 9615 | 0.040 |
Why?
|
Enterochromaffin-like Cells | 1 | 1998 | 4 | 0.040 |
Why?
|
Postoperative Complications | 1 | 2021 | 15832 | 0.040 |
Why?
|
Tumor Burden | 2 | 2015 | 1906 | 0.040 |
Why?
|
Polyomavirus Infections | 1 | 2020 | 192 | 0.040 |
Why?
|
Area Under Curve | 2 | 2013 | 1643 | 0.040 |
Why?
|
Receptors, Cholecystokinin | 1 | 1997 | 18 | 0.040 |
Why?
|
Enterochromaffin Cells | 1 | 1997 | 12 | 0.040 |
Why?
|
Anilides | 1 | 2021 | 413 | 0.040 |
Why?
|
Cell Transformation, Neoplastic | 2 | 1998 | 2846 | 0.040 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2015 | 9015 | 0.040 |
Why?
|
Mice | 7 | 2023 | 82029 | 0.040 |
Why?
|
Adenomatous Polyposis Coli | 1 | 1999 | 219 | 0.040 |
Why?
|
Receptors, Transforming Growth Factor beta | 1 | 1999 | 304 | 0.040 |
Why?
|
Tumor Virus Infections | 1 | 2020 | 437 | 0.040 |
Why?
|
Colitis, Ulcerative | 2 | 2001 | 1926 | 0.040 |
Why?
|
Patient Preference | 2 | 2017 | 946 | 0.040 |
Why?
|
Apoptosis | 4 | 2015 | 9523 | 0.040 |
Why?
|
Cell Compartmentation | 1 | 1998 | 383 | 0.040 |
Why?
|
Adenomatous Polyposis Coli Protein | 1 | 1998 | 182 | 0.040 |
Why?
|
Stomach Neoplasms | 2 | 1998 | 1481 | 0.040 |
Why?
|
Injections | 1 | 2020 | 840 | 0.030 |
Why?
|
Child | 2 | 2022 | 80917 | 0.030 |
Why?
|
Cell Survival | 2 | 2018 | 5777 | 0.030 |
Why?
|
Cell Movement | 2 | 2018 | 5210 | 0.030 |
Why?
|
Cesium Radioisotopes | 1 | 2016 | 38 | 0.030 |
Why?
|
Exons | 2 | 1999 | 2394 | 0.030 |
Why?
|
Health Physics | 1 | 2016 | 37 | 0.030 |
Why?
|
Introns | 1 | 1999 | 966 | 0.030 |
Why?
|
Brain Neoplasms | 1 | 2017 | 9118 | 0.030 |
Why?
|
beta Catenin | 2 | 1998 | 1047 | 0.030 |
Why?
|
Fibroblast Growth Factor 2 | 2 | 2012 | 590 | 0.030 |
Why?
|
Hospitals, Veterans | 1 | 2018 | 395 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 5 | 2021 | 20760 | 0.030 |
Why?
|
CD4 Lymphocyte Count | 1 | 2022 | 2596 | 0.030 |
Why?
|
Mass Screening | 2 | 2022 | 5458 | 0.030 |
Why?
|
Hot Temperature | 1 | 2022 | 1441 | 0.030 |
Why?
|
Angiogenesis Inhibitors | 1 | 2005 | 2056 | 0.030 |
Why?
|
Genes, p53 | 1 | 1998 | 714 | 0.030 |
Why?
|
Organizations, Nonprofit | 1 | 2015 | 105 | 0.030 |
Why?
|
Endodeoxyribonucleases | 1 | 2016 | 165 | 0.030 |
Why?
|
Sequence Deletion | 1 | 1999 | 1497 | 0.030 |
Why?
|
Adolescent | 4 | 2020 | 89169 | 0.030 |
Why?
|
Proteus mirabilis | 1 | 2014 | 24 | 0.030 |
Why?
|
Protein Kinase C-alpha | 1 | 2014 | 113 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2022 | 2359 | 0.030 |
Why?
|
Integrins | 1 | 1998 | 842 | 0.030 |
Why?
|
Immunohistochemistry | 4 | 2019 | 11095 | 0.030 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2018 | 757 | 0.030 |
Why?
|
Point Mutation | 1 | 1999 | 1596 | 0.030 |
Why?
|
Coitus | 1 | 2014 | 132 | 0.030 |
Why?
|
Decision Making | 2 | 2018 | 3953 | 0.030 |
Why?
|
Kinetics | 1 | 2021 | 6329 | 0.030 |
Why?
|
Meta-Analysis as Topic | 1 | 2018 | 1363 | 0.030 |
Why?
|
Gastrointestinal Hemorrhage | 2 | 2011 | 1126 | 0.030 |
Why?
|
Sample Size | 1 | 2016 | 846 | 0.030 |
Why?
|
Sex Factors | 2 | 2019 | 10632 | 0.030 |
Why?
|
United States Food and Drug Administration | 1 | 2021 | 1673 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor C | 1 | 2013 | 125 | 0.030 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2016 | 794 | 0.030 |
Why?
|
Cell Proliferation | 2 | 2018 | 10474 | 0.030 |
Why?
|
Mice, Nude | 1 | 1999 | 3623 | 0.030 |
Why?
|
Aftercare | 1 | 2018 | 916 | 0.020 |
Why?
|
Calibration | 1 | 2015 | 819 | 0.020 |
Why?
|
Inflammation | 1 | 2012 | 10873 | 0.020 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2014 | 640 | 0.020 |
Why?
|
Mice, Inbred C57BL | 3 | 2005 | 22379 | 0.020 |
Why?
|
Observer Variation | 1 | 2018 | 2622 | 0.020 |
Why?
|
DNA Replication | 1 | 1999 | 1427 | 0.020 |
Why?
|
Research Personnel | 1 | 2016 | 589 | 0.020 |
Why?
|
Diffusion of Innovation | 1 | 2016 | 724 | 0.020 |
Why?
|
Triage | 1 | 2018 | 997 | 0.020 |
Why?
|
Credentialing | 1 | 2012 | 114 | 0.020 |
Why?
|
Transplantation, Homologous | 1 | 2020 | 4833 | 0.020 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2018 | 1656 | 0.020 |
Why?
|
Hydronephrosis | 1 | 2013 | 274 | 0.020 |
Why?
|
Receptors, Androgen | 1 | 2018 | 1089 | 0.020 |
Why?
|
Vaginal Smears | 1 | 2014 | 505 | 0.020 |
Why?
|
Proctitis | 1 | 2011 | 40 | 0.020 |
Why?
|
Radiopharmaceuticals | 1 | 2021 | 2735 | 0.020 |
Why?
|
Transforming Growth Factor beta | 1 | 1999 | 1996 | 0.020 |
Why?
|
Qualitative Research | 2 | 2012 | 3140 | 0.020 |
Why?
|
Transfection | 1 | 1999 | 5755 | 0.020 |
Why?
|
Bleomycin | 1 | 2012 | 492 | 0.020 |
Why?
|
Pandemics | 2 | 2022 | 8748 | 0.020 |
Why?
|
Palladium | 1 | 2011 | 67 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 1999 | 1885 | 0.020 |
Why?
|
Transplantation, Heterologous | 1 | 1999 | 2393 | 0.020 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2012 | 300 | 0.020 |
Why?
|
Etoposide | 1 | 2012 | 639 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2021 | 5315 | 0.020 |
Why?
|
Monte Carlo Method | 1 | 2016 | 1259 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2023 | 3948 | 0.020 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2014 | 879 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2019 | 20227 | 0.020 |
Why?
|
Cervix Uteri | 1 | 2014 | 577 | 0.020 |
Why?
|
Colic | 1 | 2010 | 43 | 0.020 |
Why?
|
Lymphatic Diseases | 1 | 2012 | 319 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2016 | 3436 | 0.020 |
Why?
|
Altruism | 1 | 2012 | 211 | 0.020 |
Why?
|
Chemokine CXCL12 | 1 | 2012 | 457 | 0.020 |
Why?
|
Neoplasm, Residual | 1 | 2015 | 1015 | 0.020 |
Why?
|
Cell Cycle | 1 | 2018 | 2932 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2023 | 3833 | 0.020 |
Why?
|
Immobilization | 1 | 2010 | 229 | 0.020 |
Why?
|
Up-Regulation | 1 | 2018 | 4146 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2001 | 5797 | 0.020 |
Why?
|
Sex Characteristics | 1 | 2020 | 2650 | 0.020 |
Why?
|
DNA | 1 | 2023 | 7214 | 0.020 |
Why?
|
Regeneration | 1 | 1998 | 1524 | 0.020 |
Why?
|
Radioisotopes | 1 | 2011 | 517 | 0.020 |
Why?
|
Models, Genetic | 1 | 1999 | 3447 | 0.020 |
Why?
|
Morbidity | 1 | 2015 | 1755 | 0.020 |
Why?
|
Prostheses and Implants | 1 | 2016 | 1276 | 0.020 |
Why?
|
Rotation | 1 | 2010 | 517 | 0.020 |
Why?
|
Interleukin-8 | 1 | 2012 | 704 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2023 | 3533 | 0.020 |
Why?
|
Benzimidazoles | 1 | 2014 | 864 | 0.020 |
Why?
|
Defecation | 1 | 2010 | 191 | 0.020 |
Why?
|
Vagina | 1 | 2014 | 850 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 560 | 0.020 |
Why?
|
Polymorphism, Genetic | 1 | 1999 | 4249 | 0.020 |
Why?
|
Benchmarking | 1 | 2015 | 1057 | 0.020 |
Why?
|
Homeodomain Proteins | 1 | 2018 | 2429 | 0.020 |
Why?
|
Pelvic Bones | 1 | 2010 | 274 | 0.020 |
Why?
|
Muridae | 2 | 1998 | 55 | 0.020 |
Why?
|
Reference Values | 1 | 2015 | 4938 | 0.020 |
Why?
|
Erectile Dysfunction | 1 | 2011 | 437 | 0.020 |
Why?
|
Early Detection of Cancer | 1 | 2022 | 3239 | 0.020 |
Why?
|
Quinazolines | 1 | 2014 | 1373 | 0.020 |
Why?
|
Iodine Radioisotopes | 1 | 2011 | 1034 | 0.020 |
Why?
|
Information Dissemination | 1 | 2015 | 1143 | 0.020 |
Why?
|
Subcutaneous Fat | 1 | 2010 | 404 | 0.020 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 1998 | 3610 | 0.020 |
Why?
|
Computational Biology | 1 | 2019 | 3568 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2018 | 22291 | 0.020 |
Why?
|
California | 1 | 2011 | 1438 | 0.020 |
Why?
|
Reimbursement, Incentive | 1 | 2012 | 541 | 0.020 |
Why?
|
Histamine H2 Antagonists | 2 | 1998 | 169 | 0.020 |
Why?
|
Phantoms, Imaging | 1 | 2015 | 2512 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 1767 | 0.020 |
Why?
|
Pseudomonas aeruginosa | 1 | 2014 | 1276 | 0.020 |
Why?
|
Interleukin-1beta | 1 | 2012 | 1027 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2020 | 12465 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2018 | 10760 | 0.020 |
Why?
|
Linear Models | 1 | 2016 | 5884 | 0.020 |
Why?
|
Protein Binding | 1 | 1998 | 9343 | 0.020 |
Why?
|
Crohn Disease | 1 | 1998 | 2295 | 0.020 |
Why?
|
Acute Disease | 1 | 2016 | 7243 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2014 | 3611 | 0.020 |
Why?
|
Disease Models, Animal | 1 | 2005 | 18349 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2016 | 5902 | 0.020 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2018 | 3390 | 0.020 |
Why?
|
Kidney Transplantation | 1 | 2020 | 4262 | 0.020 |
Why?
|
Contrast Media | 1 | 2018 | 5330 | 0.010 |
Why?
|
Mitochondria | 1 | 2018 | 3681 | 0.010 |
Why?
|
Growth Inhibitors | 1 | 2005 | 375 | 0.010 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2008 | 12252 | 0.010 |
Why?
|
Femur | 1 | 2010 | 1321 | 0.010 |
Why?
|
Genetic Variation | 1 | 1999 | 6611 | 0.010 |
Why?
|
Abdominal Pain | 1 | 2010 | 1070 | 0.010 |
Why?
|
Molecular Targeted Therapy | 1 | 2015 | 2830 | 0.010 |
Why?
|
Body Weight | 1 | 2014 | 4627 | 0.010 |
Why?
|
Diarrhea | 1 | 2010 | 1320 | 0.010 |
Why?
|
Cyclohexanes | 1 | 2003 | 151 | 0.010 |
Why?
|
Residence Characteristics | 1 | 2012 | 2118 | 0.010 |
Why?
|
Cell Adhesion Molecules | 2 | 1999 | 1613 | 0.010 |
Why?
|
Proliferating Cell Nuclear Antigen | 1 | 2003 | 284 | 0.010 |
Why?
|
Triazoles | 2 | 1998 | 904 | 0.010 |
Why?
|
Sesquiterpenes | 1 | 2003 | 175 | 0.010 |
Why?
|
Motivation | 1 | 2012 | 2020 | 0.010 |
Why?
|
Health Policy | 1 | 2014 | 2698 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2018 | 7876 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2012 | 3228 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2012 | 3514 | 0.010 |
Why?
|
Laparoscopy | 1 | 2012 | 2041 | 0.010 |
Why?
|
Endothelium | 1 | 2003 | 768 | 0.010 |
Why?
|
Mice, SCID | 1 | 2005 | 2627 | 0.010 |
Why?
|
Blotting, Western | 2 | 1998 | 5027 | 0.010 |
Why?
|
Polymerase Chain Reaction | 2 | 2001 | 6082 | 0.010 |
Why?
|
Cause of Death | 1 | 2010 | 3721 | 0.010 |
Why?
|
gamma Catenin | 1 | 1998 | 45 | 0.010 |
Why?
|
Catenins | 1 | 1998 | 44 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2014 | 13014 | 0.010 |
Why?
|
Fibromatosis, Aggressive | 1 | 1999 | 125 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2016 | 15948 | 0.010 |
Why?
|
Microcirculation | 1 | 2003 | 1281 | 0.010 |
Why?
|
Codon | 1 | 1999 | 599 | 0.010 |
Why?
|
Phosphoserine | 1 | 1997 | 204 | 0.010 |
Why?
|
Recurrence | 1 | 2010 | 8509 | 0.010 |
Why?
|
Blotting, Southern | 1 | 1998 | 775 | 0.010 |
Why?
|
Phosphotyrosine | 1 | 1997 | 458 | 0.010 |
Why?
|
Hepatocytes | 1 | 2003 | 1247 | 0.010 |
Why?
|
Immunoenzyme Techniques | 1 | 1998 | 1703 | 0.010 |
Why?
|
HIV-1 | 1 | 2013 | 6961 | 0.010 |
Why?
|
Lung | 1 | 2014 | 10099 | 0.010 |
Why?
|
Family Health | 1 | 1999 | 1255 | 0.010 |
Why?
|
Epithelium | 1 | 1998 | 1607 | 0.010 |
Why?
|
DNA Primers | 1 | 1998 | 2828 | 0.010 |
Why?
|
Random Allocation | 1 | 1998 | 2396 | 0.010 |
Why?
|
RNA, Messenger | 2 | 1998 | 12800 | 0.010 |
Why?
|
DNA, Neoplasm | 1 | 1998 | 1744 | 0.010 |
Why?
|
Gene Frequency | 1 | 1999 | 3623 | 0.010 |
Why?
|
Gene Deletion | 1 | 1999 | 2675 | 0.010 |
Why?
|
Cell Division | 1 | 1999 | 4473 | 0.010 |
Why?
|
DNA Mutational Analysis | 1 | 1999 | 4120 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 1998 | 4580 | 0.010 |
Why?
|
Colon | 1 | 1998 | 1801 | 0.010 |
Why?
|
Phosphoproteins | 1 | 1998 | 2451 | 0.010 |
Why?
|
Adenoma | 1 | 1999 | 2159 | 0.000 |
Why?
|
Base Sequence | 1 | 1999 | 12421 | 0.000 |
Why?
|
Alleles | 1 | 1999 | 6894 | 0.000 |
Why?
|
Gene Expression | 1 | 2001 | 7598 | 0.000 |
Why?
|
Liver | 1 | 2003 | 7577 | 0.000 |
Why?
|
Phosphorylation | 1 | 1997 | 8317 | 0.000 |
Why?
|
Amino Acid Sequence | 1 | 1998 | 13421 | 0.000 |
Why?
|
Molecular Sequence Data | 1 | 1998 | 17622 | 0.000 |
Why?
|
Pregnancy | 1 | 2005 | 30256 | 0.000 |
Why?
|